Orexo Q2: Potentially stabilizing revenues - Redeye

CORRECTED NUMBER

Redeye maintains its valuation and positive view of Orexo after the Q2 report. Furthermore, we are encouraged to learn that the final implementation of the necessary administrative procedures related to Orexo’s digital health solutions has resulted in the first patients being identified to receive vorvida® or deprexis®.

Länk till analysen i sin helhet: https://www.redeye.se/research/848677/orexo-q2-potentially-stabilizing-revenues?utm_source=finwire&utm_medium=RSS